Navigation Links
Fixed C-Arms Revolutionize Operating Room Environments
Date:2/21/2008

ming complex, time-sensitive procedures.

About Millennium Research Group

Millennium Research Group (http://www.MRG.net), a Decision Resources, Inc. company (http://www.DecisionResources.com), is the global authority on medical technology market intelligence and a leading provider of strategic information to the health care sector. Focused solely on the medical device, pharmaceutical, and biotechnology industries, the company provides its clients with the benefits of its specialized industry expertise through published reports and customized consulting services.

All company, brand, or product names contained in this document may be

trademarks or registered trademarks of their respective holders

For more information, contact:

Amy Krohn

Millennium Research Group

416-364-7776 x101

akrohn@mrg.net


'/>"/>
SOURCE Millennium Research Group
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. ActivBiotics Completes Sale of Fixed Assets; Expands Due Diligence Initiative for the Sale of Intellectual Property, Including Drug Product Candidates
2. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
3. 3-D photonic crystals will revolutionize telecommunications
4. Siemens New S Class Revolutionizes the Paradigm of Ultrasound Workflow Today and Tomorrow
5. Nanotechnology innovation may revolutionize gene detection in a single cell
6. Former Banc of America Securities Analyst David Maris Comments on Decision by Biovail to Drop Its Claims Against Him; Denies That He is Cooperating With Biovail
7. Millennium Biotechnologies Group, Inc. (MBTG.OB) Announces Appointment of Mark C. Mirken as its President and Chief Operating Officer
8. Symmetry Medical Discloses Accounting Issues at Sheffield, UK Operating Unit and Possible Restatement
9. Novo Nordisk Increased Operating Profit by 11% in the First Nine Months of 2007 Based on a 9% Sales Increase and an Improved Gross Margin
10. Ardea Biosciences, Inc. Reports Third Quarter 2007 Operating and Financial Results
11. Isis Announces Appointment of B. Lynne Parshall as Chief Operating Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation ... development company specializing in oncology, today announced positive ... trial with aldoxorubicin for the treatment of unresectable ... cancer.  The open-label, multisite trial is designed to ... in patients whose tumors have progressed following prior ...
(Date:5/21/2015)... (PRWEB) May 21, 2015 Tunnell ... joined the firm as senior statistician and Principal, a ... of experience in the management and analysis of complex ... and chemical industries. , “We’re delighted to have Julia ... in data analytics,” said Dr. Philippe Cini, Group Vice ...
(Date:5/20/2015)... May 20, 2015  Select Medical Corporation ("Select") ... Trade Commission granted early termination of the waiting ... of 1976, as amended, applicable to the acquisition ... a joint venture that Select has created with ... As previously announced, MJ Acquisition Corporation has signed ...
(Date:5/20/2015)... , May 20, 2015  Haemonetics Corporation (NYSE: ... President & CEO, will present at The Jefferies 2015 ... on June 1 st , 2015 at 8:30am ... Mr. Concannon,s presentation live via webcast at: ... (NYSE: HAE ) is a global healthcare company ...
Breaking Biology Technology:CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Julia O’Neill Joins Tunnell Consulting’s Operational and Process Improvement Practice 2Select Medical Corporation's Proposed Acquisition of Concentra Inc. through Joint Venture with Welsh Carson Receives Antitrust Clearance 2
... N.C., June 3 Inclinix, Inc. a contract,research ... the,clinical trials of new drugs, today announced restructuring ... a growth rate of,40% in 2007 and the ... in January from Frontier Capital, a private equity ...
... June 3 NeurogesX, Inc.,(Nasdaq: NGSX ), ... pain management therapies, announced that it,submitted an investigational ... Drug Administration for the clinical development of NGX-1998, ... capsaicin. The Company further announced that the IND ...
... ... ... Paul LaViolette to retire from Company, NATICK, Mass., June ... Tobin will be extending his tenure at the Company. The Company,said Tobin plans to remain in ...
Cached Biology Technology:Inclinix Expansion Creates New Position and Promotions 2NeurogesX Opens Investigational New Drug Application for Capsaicin Liquid Formulation NGX-1998 2NeurogesX Opens Investigational New Drug Application for Capsaicin Liquid Formulation NGX-1998 3Boston Scientific Announces CEO Jim Tobin to Extend Tenure 2Boston Scientific Announces CEO Jim Tobin to Extend Tenure 3Boston Scientific Announces CEO Jim Tobin to Extend Tenure 4Boston Scientific Announces CEO Jim Tobin to Extend Tenure 5
(Date:5/20/2015)... 20, 2015 ... announced the addition of the  "5-year ... Recognition Market"  report to their offering.  ... service analyses trends in the iris ... commercial sectors, globally. Despite hardware pricing ...
(Date:5/19/2015)... 19, 2015  Technology is rapidly advancing, outpacing enterprises, ... the cloud. Passwords and their management are soon to ... standards-based specifications such as those developed by the FIDO ... passwords presents for BYOD, COPE, IoT, and mobile payments, ... protocol. In response to the call ...
(Date:5/14/2015)... Research and Markets ( http://www.researchandmarkets.com/research/5whpxg/fingerprint ) ... Market in Smart Mobile Devices " report to ... was a watershed year for fingerprint sensors in smartphones ... Apple gave fingerprint sensors a raison d,etre in the ... are a must-have feature in flagship smartphones. ...
Breaking Biology News(10 mins):Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 2HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 3Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2
... new microfluidic device may help clinicians improve a promising ... to fight such diseases as metastatic melanoma, non-Hodgkin,s lymphoma, ... as adoptive T cell transfer, has shown encouraging results ... cells called T cells from a cancer patient, multiplying ...
... a key gene mutation responsible for type 2 diabetes in ... The study, which originated in Italy and was validated at ... a major drop in the body,s ability to make insulin ... cell to absorb sugar. This drop in insulin receptors leads ...
... locations up to 50km away, a new study published in ... has found. Re-analysing tracking data from tagged sharks, ecologists found ... in a pattern known as a "random walk", others such ... mates by using "directed walks", accurately navigating long distances across ...
Cached Biology News:Researchers predict age of T cells to improve cancer treatment 2Researchers predict age of T cells to improve cancer treatment 3Type 2 diabetes linked to single gene mutation in 1 in 10 patients 2Shark tracking reveals impressive feats of navigation 2